Study of INBRX-109 in Conventional Chondrosarcoma

Description

Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.

Conditions

Conventional Chondrosarcoma

Talk to us

Study Overview

On this page

Study Details

Study overview

Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

Study of INBRX-109 in Conventional Chondrosarcoma

Condition
Conventional Chondrosarcoma
Intervention / Treatment

-

Contacts and Locations

Phoenix

Mayo Clinic Cancer Center, Phoenix, Arizona, United States, 85054

San Francisco

University of California, San Francisco (UCSF), San Francisco, California, United States, 94110

Santa Monica

Sarcoma Oncology Center, Santa Monica, California, United States, 90403

Denver

University of Colorado, Denver, Colorado, United States, 80220

Jacksonville

Mayo Clinic - Jacksonville, Jacksonville, Florida, United States, 32224

Tampa

Moffitt Cancer Center, Tampa, Florida, United States, 33612

Chicago

Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States, 60611

Chicago

Rush Cancer Center, Chicago, Illinois, United States, 60612

Iowa City

University of Iowa, Iowa City, Iowa, United States, 52242

Baltimore

Johns Hopkins, Baltimore, Maryland, United States, 21287

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Conventional chondrosarcoma, unresectable (=inoperable) or metastatic.
  • 2. Measurable disease by RECISTv1.1. Note: Tumor lesions located in a previously irradiated (or other locally treated) area will be considered measurable, provided there has been clear imaging-based progression of the lesions since the time of treatment.
  • 3. Radiologic progression of disease per RECISTv1.1 criteria within 6 months prior to screening for this study.
  • 4. Adequate hematologic, coagulation, hepatic and renal function as defined per protocol.
  • 5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
  • 6. Estimated life expectancy of at least 12 weeks.
  • 7. Availability of archival tissue or fresh cancer biopsy are mandatory.
  • 1. Any prior exposure to DR5 agonists.
  • 2. Allergy or sensitivity to INBRX-109 or known allergies to CHO-produced antibodies.
  • 3. Non-conventional chondrosarcoma, e.g., clear-cell, mesenchymal, extraskeletal myxoid, myxoid, and dedifferentiated chondrosarcoma.
  • 4. Prior or concurrent malignancies. Exception: Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments.
  • 5. Chronic liver diseases. Exception: Patients with fatty liver disease are acceptable as long as adequate hepatic function as defined in the inclusion/exclusion criteria is confirmed.
  • 6. Evidence or history of multiple sclerosis (MS) or other demyelinating disorders.
  • 7. Other exclusion criteria per protocol.

Ages Eligible for Study

18 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Inhibrx Biosciences, Inc,

Clinical Lead, STUDY_DIRECTOR, Inhibrx Biosciences, Inc

Study Record Dates

2025-07